Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Metastatic Colorectal Cancer
100%
Colorectal Carcinoma
71%
Chemotherapy
65%
Overall Survival
57%
Malignant Neoplasm
34%
Cetuximab
33%
Tumor
30%
Metastatic Carcinoma
28%
Non Small Cell Lung Cancer
28%
Progression Free Survival
28%
Diseases
22%
Radiation Therapy
21%
Clinical Trial
20%
Biological Marker
20%
Chemoradiotherapy
20%
Hazard Ratio
19%
Cancer Registry
18%
Breast Cancer
17%
Cisplatin
16%
Cancer
16%
Cancer Therapy
16%
Arm
15%
Rectum Cancer
15%
Fluorouracil
15%
Circulating Tumor DNA
13%
Fluoropyrimidine
13%
Meta-Analysis
13%
Randomized Controlled Trial
12%
Epidermal Growth Factor Receptor
12%
Panitumumab
12%
Pooled Analysis
11%
Immune Checkpoint Inhibitor
11%
Recurrent Disease
11%
Cancer Survival
11%
Supportive Care
11%
Primary Tumor
11%
Group Trial
10%
Lung
10%
Systemic Therapy
10%
Clinician
10%
Quality of Life
10%
Medical Oncology
9%
Hepatectomy
9%
Bevacizumab
8%
Phase II Trials
8%
Oncology
8%
Irinotecan
8%
Liver Metastasis
8%
Adjuvant Therapy
7%
Proton-Pump Inhibitor
7%
Pharmacology, Toxicology and Pharmaceutical Science
Metastatic Colorectal Cancer
62%
Chemotherapy Regimen
53%
Colorectal Carcinoma
41%
Cetuximab
40%
Overall Survival
37%
Progression Free Survival
32%
Epidermal Growth Factor Receptor
29%
Malignant Neoplasm
24%
Biological Marker
20%
Clinical Trial
19%
Irinotecan
18%
Diseases
17%
Non Small Cell Lung Cancer
16%
Fluoropyrimidine
16%
Bevacizumab
15%
Fluorouracil
12%
Group Trial
12%
Chemoradiation Therapy
12%
Cisplatin
12%
Atezolizumab
11%
Monoclonal Antibody
11%
Oxaliplatin
10%
Adverse Event
10%
Randomized Controlled Trial
9%
Placebo
9%
Panitumumab
8%
Proton Pump Inhibitor
7%
Abdominal Cancer
7%
Neoplasm
7%
Pharmacokinetic
7%
Immune Checkpoint Inhibitor
7%
Paclitaxel
6%
Capecitabine
6%
Colon Carcinoma
6%
Primary Tumor
6%
Durvalumab
5%
Breast Cancer
5%
Rash
5%
Nursing and Health Professions
Metastatic Colorectal Cancer
38%
Chemotherapy
35%
Colorectal Carcinoma
21%
Malignant Neoplasm
20%
Overall Survival
17%
Efficacy
8%
Clinical Trial
8%
Cancer Registry
8%
Nutrition
8%
Cancer Therapy
7%
Breast Cancer
7%
Biological Marker
6%
Public Hospital
6%
Epidermal Growth Factor Receptor
6%
Diseases
6%
Cancer Survival
6%
Pilot Study
5%
Physical Activity
5%
Primary Tumor
5%
Fluorouracil
5%
Hazard Ratio
5%
Cetuximab
5%